Kiechi and co-authors reported that blockade of RANKL improved hepatic insulin resistance and prevented DM development in an in vivo study.[10] However, the effect of denosumab upon glycemic and metabolic parameters in humans is not clear. Here, TNFSF11 is linked to Insulin resistance.